Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab

Background & Aims: Atezolizumab/bevacizumab (A/B) is now a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but the optimal second-line regimen is not known. We evaluated real-world treatment patterns and outcomes to investigate factors associated with post-progress...

Full description

Saved in:
Bibliographic Details
Main Authors: Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JHEP Reports
Subjects:
Hepatocellular carcinoma
atezolizumab
bevacizumab
second-line therapy
immune checkpoint inhibitors
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555924002362
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items